Education
About Us
Working with TipRanks
Follow Us
Tscan Therapeutics, Inc. (TCRX)
:TCRX
TCRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.02 - $6.23
Previous CloseN/A
Volume150.47K
Average Volume (3M)258.85K
Market Cap
$95.34M
Enterprise Value$66.76M
Total Cash (Recent Filing)$218.04M
Total Debt (Recent Filing)$64.40M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Nov 05, 2025EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding52,471,405
10 Day Avg. Volume210,448
30 Day Avg. Volume258,847
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue9.59
Enterprise Value/Gross Profit10.68
Enterprise Value/Ebitda-0.51
Forecast
1Y Price Target
$7.10Price Target Upside308.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementTSC-100/101 continued to strongly favor the treatment arm, with a significantly lower relapse rate compared to the control arm.
Financial StabilityThe company ended with $218M, supporting operations into the future.
Regulatory ProgressTCRX remains on track for a meeting with the FDA to discuss details for the pivotal study of TSC-101, with study start still planned.
Bears Say
Clinical ChallengesInitial data for the multiplex solid tumor program has been pushed out, indicating challenges in identifying suitable patients.
Statistical SignificanceThe 23% vs. 58% probability of relapse did not meet statistical significance, likely due to the short duration of follow-up and small patient population.
TScan Therapeutics News
TCRX FAQ
What was Tscan Therapeutics, Inc.’s price range in the past 12 months?
Tscan Therapeutics, Inc. lowest stock price was $1.02 and its highest was $6.22 in the past 12 months.
What is Tscan Therapeutics, Inc.’s market cap?
Tscan Therapeutics, Inc.’s market cap is $95.34M.
When is Tscan Therapeutics, Inc.’s upcoming earnings report date?
Tscan Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2025 which is in 74 days.
How were Tscan Therapeutics, Inc.’s earnings last quarter?
Tscan Therapeutics, Inc. released its earnings results on Aug 12, 2025. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.327 by $0.047.
Is Tscan Therapeutics, Inc. overvalued?
According to Wall Street analysts Tscan Therapeutics, Inc.’s price is currently Undervalued.
Does Tscan Therapeutics, Inc. pay dividends?
Tscan Therapeutics, Inc. does not currently pay dividends.
What is Tscan Therapeutics, Inc.’s EPS estimate?
Tscan Therapeutics, Inc.’s EPS estimate is -0.33.
How many shares outstanding does Tscan Therapeutics, Inc. have?
Tscan Therapeutics, Inc. has 52,471,405 shares outstanding.
What happened to Tscan Therapeutics, Inc.’s price movement after its last earnings report?
Tscan Therapeutics, Inc. reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.327. Following the earnings report the stock price went up 3.727%.
Which hedge fund is a major shareholder of Tscan Therapeutics, Inc.?
Currently, no hedge funds are holding shares in TCRX
TScan Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.10 (308.05% Upside)
$7.10 (308.05% Upside)
Blogger Sentiment
Bullish
TCRX Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.1%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.45%
12-Months-Change
Fundamentals
Return on Equity
-63.33%
Trailing 12-Months
Asset Growth
-20.36%
Trailing 12-Months
Company Description
Tscan Therapeutics, Inc.
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TCRX Stock 12 Month Forecast
Average Price Target
$7.10
▲(308.05% Upside)
Technical Analysis
Adverum Biotechnologies
―
Elicio Therapeutics
―
Adagene
―
Context Therapeutics
―
Rani Therapeutics Holdings
―
Ownership Overview
20.26% Insiders
8.25% Mutual Funds
44.74% Other Institutional Investors
19.95% Public Companies and Individual Investors
Options Prices
Currently, No data available
---